tiprankstipranks
Leadership Changes and Stockholder Decisions at TScan Therapeutics
Company Announcements

Leadership Changes and Stockholder Decisions at TScan Therapeutics

Don't Miss our Black Friday Offers:

TScan Therapeutics (TCRX) has issued an update.

At TScan Therapeutics’ Annual Meeting on June 12, 2024, significant board changes were made as Timothy Barberich stepped down as Chairman and board member, with Stephen Biggar taking over as Chairman. Garry Nicholson joined as an independent director and received an option grant for company shares, aligning with the company’s compensation policy. Additionally, the stockholders approved an amended equity incentive plan, increasing available shares and including pre-funded warrants in annual share replenishment calculations. The meeting also saw the election of Class III directors and the ratification of the company’s independent accounting firm.

See more insights into TCRX stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskTScan Therapeutics Reports Q3 2024 Financial Results
TheFlyTScan Therapeutics reports Q3 EPS (25c), consensus (29c)
TheFlyTScan Therapeutics announces preliminary results from ALLOHA Phase 1 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App